SELLAS Life Sciences Group, Inc. SLS
Nov 12, 2026, 1:27 PM EST
- YTD
- +117.11%
- 1 year
- +449.33%
Discussion (328)
Sign in to join the discussion
$SLS Will one of you shorties please sell me calls I’m buying the $9.5 x100 for $1 each. Dated 3/27 & 4/3 it’s an easy $200 for you! Otherwise do not post your fake shorts theory!
$SLS these sh!t shorts really don’t understand this stock. It will move upwards and onwards. 7$ by EOW. So sh!t shorts there’s nothing you can do. Go short a different stock. This one is way out your league!
JPMorgan warned of a 10% correction in the S&P 500 from its peak because of the Iran war
https://youtube.com/shorts/eDHfFQBPwbY?feature=share
$SLS Announcement from Merck:
Merck announced on Monday that it will split its operations into two divisions. This will create an independent division for the cancer business, led by the blockbuster drug Keytruda, while the non-oncology treatments will be bundled separately.
The restructuring underscores the U.S. pharmaceutical company's ambition to diversify beyond Keytruda and other established drugs as key patents are about to expire. Merck has tripled its pipeline since 2021 and last year acquired Cidara Therapeutics as well as Verona Pharma in deals worth around $10 billion to expand the portfolio. The company's shares remained almost unchanged in early trading.
The realignment could pave the way for bigger moves in the long term than the stock market's muted reaction suggests, said James Harlow, senior vice president at Novare Capital Management.
"The company now has more options to spin off or spin off one of these businesses in the future," Harlow said.
The pharmaceutical company had already spun off its women's health and biosimilars business into a standalone company called Organon in 2021. However, the current split does not affect the animal health division.
Merck's key growth driver Keytruda, which is approved for various types of cancer, is the world's best-selling prescription drug. The treatment generated over $30 billion in sales in 2025, accounting for nearly half of the company's total revenue.
Analysts at Citi said the split helps to clearly differentiate Merck's established oncology portfolio from the newer assets acquired through acquisitions. However, they warned that more efforts are needed in the areas of commercial implementation, business development and pipeline management to fully offset the upcoming pressure from the loss of exclusivity rights.
The split follows Merck's pessimistic guidance for 2026, which was released earlier this month. In it, the company warned of lower-than-expected sales and profits as several established drugs are on the verge of losing patent protection and face increasing competition from generics.
Merck has also appointed Jannie Oosthuizen as Executive Vice President and President of the Cancer business. Oosthuizen most recently served as Senior Vice President and President of Merck Human Health U.S., where he led the strategy and commercialization of the company's U.S. portfolio.
$SLS Dr. Angelos has become the Riddler. Season has come to an end = probably 80th event has happened or will happen in upcoming days. Sorry for the losses of the patients lifes but this message is clear as Budweiser (f@cking close to water)!
$SLS Supreme Court just knocked down the import tariffs imposed by Potus!
$SLS Up in Germsny by 4.48% https://live.deutsche-boerse.com/equity/sellas-life-sciences-grp-1?mic=XFRA
$SLS shut the f@ck up grandpa. Time to put you asleep ⬇️
$SLS f@cking Yanks. Y’all deserve to be shot by Border Patrol or ICE. Morons!